RAPT Therapeutics, Inc. financial data

Symbol
RAPT on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 902% % 15%
Debt-to-equity 13% % -24%
Return On Equity -62% % 31%
Return On Assets -55% % 28%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27,710,871 shares -21%
Common Stock, Shares, Outstanding 132,006,828 shares 284%
Entity Public Float $75,000,000 USD -81%
Common Stock, Value, Issued $2,000 USD -33%
Weighted Average Number of Shares Outstanding, Basic 26,963,107 shares 454%
Weighted Average Number of Shares Outstanding, Diluted 26,963,107 shares 454%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $82,872,000 USD -5.3%
General and Administrative Expense $29,764,000 USD 8.9%
Operating Income (Loss) $112,636,000 USD 1.9%
Nonoperating Income (Expense) $6,999,000 USD -4.9%
Net Income (Loss) Attributable to Parent $105,637,000 USD 1.7%
Earnings Per Share, Basic 5 USD/shares 83%
Earnings Per Share, Diluted 5 USD/shares 83%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $37,930,000 USD 0.08%
Marketable Securities, Current $119,414,000 USD 99%
Cash, Cash Equivalents, and Short-term Investments $157,300,000 USD 61%
Assets, Current $161,045,000 USD 57%
Property, Plant and Equipment, Net $765,000 USD -54%
Operating Lease, Right-of-Use Asset $1,883,000 USD -51%
Other Assets, Noncurrent $2,046,000 USD 426%
Assets $165,739,000 USD 53%
Accounts Payable, Current $2,102,000 USD 52%
Accrued Liabilities, Current $9,008,000 USD 41%
Liabilities, Current $13,375,000 USD 29%
Operating Lease, Liability, Noncurrent $387,000 USD -85%
Liabilities $13,762,000 USD 6.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax $100,000 USD -6.5%
Retained Earnings (Accumulated Deficit) $666,935,000 USD -19%
Stockholders' Equity Attributable to Parent $151,977,000 USD 59%
Liabilities and Equity $165,739,000 USD 53%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $52,414,000 USD -94%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $57,064,000 USD -459%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 132,006,828 shares 284%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $109,478,000 USD -4966%
Deferred Tax Assets, Valuation Allowance $134,582,000 USD 26%
Deferred Tax Assets, Gross $135,282,000 USD 26%
Operating Lease, Liability $4,492,000 USD -35%
Payments to Acquire Property, Plant, and Equipment $43,000 USD -59%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $105,644,000 USD 1.5%
Lessee, Operating Lease, Liability, to be Paid $4,799,000 USD -37%
Property, Plant and Equipment, Gross $11,146,000 USD -2.6%
Operating Lease, Liability, Current $2,209,000 USD -12%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,137,000 USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,662,000 USD -6.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $307,000 USD -59%
Deferred Tax Assets, Operating Loss Carryforwards $67,565,000 USD 16%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50,000,000 shares 0%
Unrecognized Tax Benefits $5,579,000 USD 19%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $18,803,000 USD -4.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%